Page last updated: 2024-10-22

aminoglutethimide and Neoplasm Metastasis

aminoglutethimide has been researched along with Neoplasm Metastasis in 104 studies

Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.

Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Research Excerpts

ExcerptRelevanceReference
"Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer."10.16Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987)
"The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer."9.09Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000)
"In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared."9.06Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989)
"One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide."9.06Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. ( Biran, S; Brufman, G, 1990)
"The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer."9.06Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986)
"Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer."9.05Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer. ( Ardizzoni, A; Conte, P; Lionetto, R; Pronzato, P; Rosso, R, 1985)
"Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND)."7.68Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. ( Ashley, SE; Coombes, RC; Ellin, CL; Hardy, JR; Judson, IR; Powles, TJ; Sinnett, HD, 1990)
"44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone."7.68[Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991)
"This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer."7.67Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987)
"Seventy-nine postmenopausal patients received aminoglutethimide (AG; 750 mg daily) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy."7.67Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. ( Gilmore, OJ; Plowman, PN; Rowell, NP, 1987)
"Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%."7.67[The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987)
"Sixty patients suffering from metastatic breast cancer, whose disease progressed on chemotherapy and/or hormonal therapy with tamoxifen, were treated with aminoglutethimide."7.67Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen. ( Biran, S; Brufman, G, 1985)
"One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)."7.67Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986)
"45 women (postmenopausal or after former oophorectomy) with metastatic breast cancer resistant to tamoxifen as well as to chemo- and radiotherapy were treated with aminoglutethimide (750 mg or 1000 mg resp."7.67[Aminoglutethimide therapy in advanced breast cancer]. ( Kühböck, J; Ludwig, H; Pötzi, P; Zielinski, C, 1985)
"Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone."7.67Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986)
"Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide."7.66Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, KC, 1982)
"We describe sequential response to aminoglutethimide after eventual failure of treatment with tamoxifen in a patient with metastatic breast cancer."7.66Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer. ( Allison, RW; Furnival, CM; Lee, JF; Roberts, SJ, 1982)
"Sixty-five patients with actively progressing advanced breast cancer were treated with aminoglutethimide, a drug which inhibits adrenal steroid synthesis and decreases peripheral conversion of androgens to oestrogens."7.66Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. ( Jerums, G; Murray, RM; Pitt, P, 1981)
"Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone."7.66Treatment of metastatic breast cancer with aminoglutethimide. ( Asbury, RF; Bakemeier, RF; Bennett, JM; Fölsch, E; McCune, CS; Savlov, E, 1981)
"Aminoglutethimide was applied for treatment of 10 patients (8 postmenopausal, 2 ovariectomized) with metastasizing breast cancer."7.66[Treatment of metastasizing breast cancer with aminoglutethimide]. ( Aiginger, P; Kübböck, J; Linkesch, W; Ludwig, H; Pötzi, P, 1982)
"Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone."7.66Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983)
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."6.36Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977)
"Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer."6.16Tamoxifen therapy of metastatic breast cancer. ( Manni, A, 1987)
"As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer."5.28[The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991)
"A total of 79 patients with metastatic breast cancer entered the study, and their plasma and urine samples were analyzed by high-performance liquid chromatography (HPLC)."5.27Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ( Höffken, K; Miller, AA; Miller, BE; Schmidt, CG, 1987)
"Aminoglutethimide is an investigational agent of proven benefit in the treatment of metastatic breast carcinoma."5.26Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. ( Hamilton, R; Harvey, HA; Lawrence, B; Lipton, A; Mercurio, T; Santen, RJ, 1978)
"The efficacy of combined endocrine therapy with tamoxifen (TAM), aminoglutethimide (AG), and hydrocortisone (H) or tamoxifen and fluoxymesterone (FLU) was evaluated against treatment with tamoxifen alone in 311 patients above 65 years of age with a first recurrence of a metastatic breast cancer."5.09Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. ( Andersen, J; Andersson, M; Bastholt, L; Christensen, IJ; Dombernowsky, P; Kamby, C; Mouridsen, HT; Munkholm, P; Møller, KA; Rose, C, 2000)
"In order to evaluate the effectiveness of second and third line hormone therapy for postmenopausal (spontaneous or surgical) women with metastatic tamoxifen-resistant breast cancer, 293 women aged 36 to 91 (mean 63."5.07[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. ( Ayme, Y; Carton, M; Daban, A; Delozier, T; Fargeot, P; Ferri, L; Fumoleau, P; Garcia-Giralt, E; Gorins, A; Omodei Zorini, C, 1994)
"The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer."5.06Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986)
"In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared."5.06Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989)
"One hundred and twenty patients with metastatic breast cancer, whose disease progressed on hormonal therapy with tamoxifen, were treated with aminoglutethimide."5.06Second line hormonal therapy with aminoglutethimide in metastatic breast cancer. ( Biran, S; Brufman, G, 1990)
"One hundred-twenty-seven advanced breast cancer patients who had been -for most of them- heavily pretreated with chemo- and/or hormone therapy received 500 mg aminoglutethimide and 30 mg hydrocortisone/day."5.06[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast]. ( Bonneterre, J; Demaille, A; Pion, JM, 1987)
"Aminoglutethimide, a drug known to block adrenal steroidogenesis and peripheral aromatization of androgens to estrogens, has been found effective in the treatment of breast cancer."5.05Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer. ( Ardizzoni, A; Conte, P; Lionetto, R; Pronzato, P; Rosso, R, 1985)
"Randomized clinical trials have established the role of third-generation aromatase inhibitors (AIs) (letrozole, anastrozole, and exemestane) as standard treatment for patients with hormone-sensitive metastatic breast cancer who have experienced disease progression with antiestrogen therapy."4.82A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. ( Rose, C, 2003)
"59 women with metastatic breast cancer in menopause were treated with 1 g/day aminoglutethimide and 3 mg/d dexamethasone."3.68[Experiences with Rodazol therapy in the treatment of postmenopausal patients with metastatic breast cancer]. ( Gürtler, R; Müller, U; Schmidt, UM; Stier, G; Tanneberger, S, 1990)
"Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND)."3.68Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. ( Ashley, SE; Coombes, RC; Ellin, CL; Hardy, JR; Judson, IR; Powles, TJ; Sinnett, HD, 1990)
"44 postmenopausal women with progressive soft tissue, osseous and/or pleuropulmonal metastases of breast cancer were treated with aminoglutethimide (Rodazol) and hydrocortisone."3.68[Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer]. ( Brockmann, B; Geschke, E; Schmidt, UM, 1991)
"Administration of orimeten (aminoglutethimide), for disseminated breast cancer in 38 postmenopausal females, in whom other treatment modalities had failed, proved effective in 39%."3.67[The use of aminoglutethimide (orimeten) in disseminated breast cancer]. ( Bassalyk, LS; Garin, AM; Lichinitser, MR; Nadezhdina, TM; Vyshinskaia, GV, 1987)
"Seventy-nine postmenopausal patients received aminoglutethimide (AG; 750 mg daily) and hydrocortisone therapy for metastatic or locally recurrent breast cancer following the failure of other hormonal therapy."3.67Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity. ( Gilmore, OJ; Plowman, PN; Rowell, NP, 1987)
"One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)."3.67Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986)
"Eighteen premenopausal patients with progressive metastatic breast cancer were treated with aminoglutethimide (AG)/cortisone."3.67Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. ( Blossey, HC; Nagel, GA; Wander, HE, 1986)
"Sixty patients suffering from metastatic breast cancer, whose disease progressed on chemotherapy and/or hormonal therapy with tamoxifen, were treated with aminoglutethimide."3.67Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen. ( Biran, S; Brufman, G, 1985)
"Postmenopausal patients with metastatic breast cancer were treated with aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA)."3.67Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol. ( Blijham, GH; Mellink, WA; Meulenberg, PM; Van Deijk, WA, 1985)
"Marked leukopenia and/or thrombocytopenia occurred in 12 of 1333 patients treated with aminoglutethimide (0."3.67Aminoglutethimide-induced hematologic toxicity: worldwide experience. ( Boucher, AE; Buzdar, AU; Harvey, HA; Henderson, IC; Lipton, A; Messeih, AA; Murray, R; Nagel, GA; Ragaz, J; Santen, RJ, 1985)
"This study was performed to determine the toxicity and effectiveness of megestrol acetate used with aminoglutethimide-hydrocortisone in the treatment of patients with metastatic breast cancer."3.67Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide. ( Gale, KE; Hahn, RG; Horton, J; Keller, AM; Knuiman, M; Rosenbluth, RJ; Tormey, DC; Vogel, H, 1987)
"45 women (postmenopausal or after former oophorectomy) with metastatic breast cancer resistant to tamoxifen as well as to chemo- and radiotherapy were treated with aminoglutethimide (750 mg or 1000 mg resp."3.67[Aminoglutethimide therapy in advanced breast cancer]. ( Kühböck, J; Ludwig, H; Pötzi, P; Zielinski, C, 1985)
"Two hundred and thirteen unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone."3.66Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. ( Coombes, RC; Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Powles, TJ; Smith, IE; White, H, 1983)
"We describe sequential response to aminoglutethimide after eventual failure of treatment with tamoxifen in a patient with metastatic breast cancer."3.66Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer. ( Allison, RW; Furnival, CM; Lee, JF; Roberts, SJ, 1982)
"In 114 patients with metastatic breast cancer resistant to chemo- and hormonal therapy another attempt was made to treat these patients with the hormone combination of aminoglutethimide (AG) 1000 mg daily and medroxyprogesteroneacetate (MAP) 1500 mg daily for 6 weeks, than 500 mg MAP daily."3.66[Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force]. ( Blossey, HC; Nagel, GA; Wander, HE, 1982)
"Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide."3.66Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. ( Blumenschein, GR; Buzdar, AU; Legha, SS; Powell, KC, 1982)
"Sixty-five patients with actively progressing advanced breast cancer were treated with aminoglutethimide, a drug which inhibits adrenal steroid synthesis and decreases peripheral conversion of androgens to oestrogens."3.66Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer. ( Jerums, G; Murray, RM; Pitt, P, 1981)
"Seventy-three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone."3.66Treatment of metastatic breast cancer with aminoglutethimide. ( Asbury, RF; Bakemeier, RF; Bennett, JM; Fölsch, E; McCune, CS; Savlov, E, 1981)
"Aminoglutethimide was applied for treatment of 10 patients (8 postmenopausal, 2 ovariectomized) with metastasizing breast cancer."3.66[Treatment of metastasizing breast cancer with aminoglutethimide]. ( Aiginger, P; Kübböck, J; Linkesch, W; Ludwig, H; Pötzi, P, 1982)
"Medical adrenalectomy, consisting of aminoglutethimide plus either dexamethasone or hydrocortisone, was administered to 53 women with advanced breast cancer."3.66Medical adrenalectomy in patients with advanced breast cancer. ( Brown, PW; Horsley, JS; Lawrence, W; Neifeld, JP; Newsome, HH; Terz, JJ, 1982)
"In conclusion, in a group of metastatic breast cancer patients, treated routinely by systemic therapies it was found, that the use of higher cut-off point for EGF-R positivity can improve the prediction of endocrine sensitivity."2.69Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. ( Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I, 2000)
"Aminoglutethimide (Elipten), at a dosage between 250 and 1500 mg/d by mouth, was administered in a clinical phase II study to 17 patients with metastasizing carcinoma of the breast resistant to hormones and cytostatic drugs."2.65[Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)]. ( Rieche, K, 1981)
"Almost all patients with prostatic cancer will eventually escape the control of the first-line endocrine therapy and relapse."2.38Management of relapsing disease in prostate cancer. ( Denis, L; Mahler, C, 1992)
" While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone."2.36Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977)
"Twenty-nine patients with metastatic prostate cancer were treated with simultaneous flutamide withdrawal and aminoglutethimide (250 mg given orally four times daily)."1.29Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. ( Cooper, M; Figg, WD; Headlee, D; Linehan, WM; Myers, CE; Sartor, O; Steinberg, S; Thibault, A; Tompkins, A; Weinberger, M, 1994)
"Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months)."1.28Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. ( Angus, B; Cairns, J; Farndon, J; Harris, AL; Horne, CH; Nicholson, S; Sainsbury, JR; Wright, C, 1992)
"As breast cancer is responsive to hormonal therapy, AG has been used in the treatment of metastatic breast cancer."1.28[The use of aminoglutethimide in the treatment of metastatic breast cancer]. ( Bellora, MG; Bergamino, T; Ciancio, A; Ferrero, A; Sismondi, P; Zola, P, 1991)
"In 57 patients with metastasized breast carcinoma, serum CEA levels (CEA-Ria-Kit, Abbot) were correlated with the clinical course under endocrine or cytostatic therapy."1.27[Prognostic value of serum CEA and therapy-induced nonspecific CEA levels in metastasizing breast carcinoma]. ( Garbrecht, M; Kleeberg, UR; Müllerleile, U; Pompecki, R; Treidler, J, 1984)
"A total of 79 patients with metastatic breast cancer entered the study, and their plasma and urine samples were analyzed by high-performance liquid chromatography (HPLC)."1.27Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. ( Höffken, K; Miller, AA; Miller, BE; Schmidt, CG, 1987)
"Hormone-dependent breast carcinomas respond to deprivation of biologically active estrogens with objectively quantifiable tumor regression."1.26Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. ( Boucher, A; Harvey, H; Lipton, A; Samojlik, E; Santen, RJ; Wells, SA; Worgul, TJ, 1982)
"Aminoglutethimide is an investigational agent of proven benefit in the treatment of metastatic breast carcinoma."1.26Pancytopenia induced by aminoglutethimide in the treatment of breast cancer. ( Hamilton, R; Harvey, HA; Lawrence, B; Lipton, A; Mercurio, T; Santen, RJ, 1978)
"42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis."1.26Aminoglutethimide in treatment of metastatic breast carcinoma. ( Fahmy, DR; Fitzharris, BM; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Neville, AM; Powles, TJ; Smith, IE, 1978)

Research

Studies (104)

TimeframeStudies, this research(%)All Research%
pre-199083 (79.81)18.7374
1990's16 (15.38)18.2507
2000's4 (3.85)29.6817
2010's1 (0.96)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kadhirvel, P1
Azenha, M1
Schillinger, E1
Halhalli, MR1
Silva, AF1
Sellergren, B1
Rose, C4
Kruit, WH1
Stoter, G1
Klijn, JG1
Buzdar, AU2
Powell, KC1
Legha, SS1
Blumenschein, GR1
Wander, HE5
Nagel, GA6
Blossey, HC4
Stuart-Harris, RC1
Smith, IE3
Treidler, J1
Pompecki, R1
Müllerleile, U1
Garbrecht, M1
Kleeberg, UR2
Santen, RJ15
Wells, SA9
Allison, RW1
Furnival, CM1
Lee, JF1
Roberts, SJ1
Mouridsen, HT3
Palshof, T1
Mattheiem, W1
Sylvester, RJ1
Rotmensz, N1
Paridaens, RJ1
Murray, RM1
Pitt, P2
Jerums, G1
Brufman, G3
Biran, S3
Harris, AL2
Powles, TJ4
Coombes, RC3
Ford, HT2
Gazet, JC2
Harmer, CL1
Morgan, M1
White, H1
Parsons, CA1
McKinna, JA2
Lipton, A12
Harvey, HA5
Boucher, A2
White, D2
Bernath, A1
Dixon, R1
Richards, G1
Shafik, A1
Szepesi, T1
Schratter-Sehn, AU1
Williams, C1
Buchanan, R1
Worgul, TJ3
Samojlik, E6
Interrante, A1
Boucher, AE3
White, DS2
Smart, E3
Cox, C2
Harvey, H5
Gordon, C1
Horsley, JS1
Newsome, HH1
Brown, PW2
Neifeld, JP1
Terz, JJ2
Lawrence, W1
Sterns, EE1
Bird, CE1
Mackie, KW1
Kübböck, J1
Ludwig, H2
Aiginger, P1
Linkesch, W1
Pötzi, P2
Asbury, RF1
Bakemeier, RF1
Fölsch, E1
McCune, CS1
Savlov, E1
Bennett, JM2
Rieche, K1
Paridaens, R1
Van Haelen, C1
Heuson, JC1
Henderson, IC2
Canellos, GP1
Sartor, O1
Cooper, M1
Weinberger, M1
Headlee, D1
Thibault, A1
Tompkins, A1
Steinberg, S1
Figg, WD1
Linehan, WM1
Myers, CE1
Freeman, DA1
Garcia-Giralt, E1
Omodei Zorini, C1
Ferri, L1
Ayme, Y1
Carton, M1
Daban, A1
Delozier, T1
Fargeot, P2
Fumoleau, P1
Gorins, A1
Pronzato, P3
Rubagotti, A1
Amoroso, D1
Bertelli, G2
Queirolo, P1
Sertoli, MR1
Rosso, M2
Gallotti, P1
Monzeglio, C1
Rosso, R2
Hultborn, R1
Johansson-Terje, I1
Bergh, J1
Glas, U1
Hallsten, L1
Hatschek, T1
Holmberg, E1
Ideström, K1
Norberg, B1
Ranstam, J1
Söderberg, M1
Wallgren, UB1
Bare, RL1
Torti, FM1
Kamby, C3
Andersson, M1
Bastholt, L2
Møller, KA1
Andersen, J1
Munkholm, P1
Dombernowsky, P2
Christensen, IJ1
Nesković-Konstantinović, ZB1
Nikolić-Vukosavljević, DB1
Branković-Magić, MV1
Mitrovic, LB1
Spuzić, I1
Fitzharris, BM1
Fahmy, DR1
Nash, AG1
Neville, AM1
Veldhuis, J1
Ruby, EB1
Kendall, J1
Lawrence, B1
Hamilton, R1
Mercurio, T1
Osterman, J1
McElduff, A1
Clifton-Bligh, P1
Posen, S1
Haagensen, DE2
Ruby, EJ1
Dilley, WG1
Koelmeyer, TD1
Stephens, EJ1
Wood, HF1
Misbin, RJ1
Misbin, R1
Wright, C1
Nicholson, S1
Angus, B1
Sainsbury, JR1
Farndon, J1
Cairns, J1
Horne, CH1
Mahler, C1
Denis, L1
Schmidt, UM2
Brockmann, B1
Geschke, E1
Bellora, MG1
Ciancio, A1
Ferrero, A1
Bergamino, T1
Zola, P1
Sismondi, P1
Namer, M1
Voznyĭ, EK1
Meshcheriakova, NG1
Biakhov, MIu1
Vasiuta, NIu1
Hardy, JR1
Judson, IR1
Sinnett, HD1
Ashley, SE1
Ellin, CL1
Stier, G1
Gürtler, R1
Müller, U1
Tanneberger, S1
Chang, AY1
Pandya, KJ1
Asbury, R1
McCune, C1
Lundgren, S1
Gundersen, S1
Klepp, R1
Lønning, PE1
Lund, E1
Kvinnsland, S1
Geller, J1
Albert, JD1
Samonigg, H1
Kleeberg, U1
Manni, A1
Essers, U1
Van Deijk, WA1
Blijham, GH1
Mellink, WA1
Meulenberg, PM1
Teichmann, AT1
Cremer, P1
Wieland, H1
Kruse, B1
Kuhn, W1
Seidel, D1
Grem, JL1
Falkson, G1
Love, RR1
Tormey, DC2
Bonneterre, J2
Pion, JM1
Demaille, A1
Horton, J1
Knuiman, M1
Keller, AM1
Vogel, H1
Gale, KE1
Hahn, RG1
Rosenbluth, RJ1
Ingle, JN1
Green, SJ1
Ahmann, DL1
Long, HJ1
Edmonson, JH1
Rubin, J1
Chang, MN1
Creagan, ET1
Brincker, H1
Skovgaard-Poulsen, H1
Andersen, AP1
Loft, H1
Andersen, KW1
Nadezhdina, TM1
Vyshinskaia, GV1
Lichinitser, MR1
Bassalyk, LS1
Garin, AM1
Rowell, NP1
Gilmore, OJ1
Plowman, PN1
Gorgone, S1
Lorenzini, C1
Palmeri, R1
Belnome, N1
Calbo, L1
Dattola, P1
Melita, P1
Crawford, ED1
Ahmann, FR1
Davis, MA1
Levasseur, YJ1
Nemoto, T1
Miller, AA3
Miller, BE1
Höffken, K3
Schmidt, CG3
Miller, B2
Becher, R2
Aulbert, E1
Hoffmann, B1
Anders, CU1
Callies, R1
Paterson, AH1
Ardizzoni, A1
Lionetto, R1
Conte, P1
Coppens, H1
Mauriac, L1
Metz, M1
Rouesse, J1
Armand, JP1
Mathieu, M1
Tubiana, M1
Cappelaere, P1
Dubost, JJ1
Sauvezie, B1
Ristori, JM1
Thevenet, JP1
Rampon, S1
Murray, R2
Messeih, AA1
Ragaz, J1
Blankenstein, MA1
Bakker, GH1
Kühböck, J1
Zielinski, C1
Carey, RM1
Orth, DN1
Hartmann, WH1
Cash, R2
Brough, AJ1
Cohen, MN1
Satoh, PS1
Schein, PS1
Corrin, B1
Gilby, ED1
Jones, NF1
Patrick, J1
Belchetz, PE1
Brown, CL1
Makin, HL1
Trafford, DJ1
Mason, AS1
Bloom, SR1
Ratcliffe, JG1
Robinson, MR2
Shearer, RJ1
Fergusson, JD1
Griffiths, CT1
Hall, TC1
Saba, Z1
Barlow, JJ1
Nevinny, HB1
Givens, JR1
Camacho, A1
Patterson, P1
Thomas, BS1
Miranda-Zetterstrand, N1
Díaz-Bonet, L1
Pagán-Sáez, H1
Rosaly de Jirau, W1
Schteingart, DE1
Conn, JW1

Reviews

12 reviews available for aminoglutethimide and Neoplasm Metastasis

ArticleYear
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast

2003
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
    Anti-cancer drugs, 2004, Volume: 15, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic C

2004
Aminoglutethimide in the treatment of advanced breast cancer.
    Cancer treatment reviews, 1984, Volume: 11, Issue:3

    Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic;

1984
[Hormones and tumor therapy: current clinical status and future developments in endocrine therapy of breast cancer].
    Wiener klinische Wochenschrift, 1982, Sep-17, Volume: 94, Issue:17

    Topics: Adrenal Cortex Hormones; Adrenalectomy; Aminoglutethimide; Androgens; Breast Neoplasms; Castration;

1982
Endocrine therapy of prostate cancer.
    Cancer treatment and research, 1998, Volume: 94

    Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Antineoplasti

1998
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
    Cancer, 1977, Volume: 39, Issue:6 Suppl

    Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy

1977
Management of relapsing disease in prostate cancer.
    Cancer, 1992, Jul-01, Volume: 70, Issue:1 Suppl

    Topics: Aminoglutethimide; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Estrogens

1992
Adrenal androgen blockade in relapsed prostate cancer.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:10

    Topics: Adrenalectomy; Aminoglutethimide; Androgen Antagonists; Castration; Combined Modality Therapy; Cypro

1985
Tamoxifen therapy of metastatic breast cancer.
    The Journal of laboratory and clinical medicine, 1987, Volume: 109, Issue:3

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin

1987
[New hormonal treatments of metastatic prostatic cancer. Review of the literature].
    Revue du rhumatisme et des maladies osteo-articulaires, 1985, Volume: 52, Issue:10

    Topics: Aminoglutethimide; Androgen Antagonists; Animals; Antineoplastic Agents; Combined Modality Therapy;

1985
[Hormone therapy of metastatic breast carcinoma].
    Deutsche medizinische Wochenschrift (1946), 1985, Nov-22, Volume: 110, Issue:47

    Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Buserelin; Female;

1985
Chemotherapeutic management of the hormone-secreting endocrine malignancies.
    Cancer, 1972, Volume: 30, Issue:6

    Topics: Adenoma, Islet Cell; Adrenal Gland Neoplasms; Aminoglutethimide; Aniline Compounds; Antibiotics, Ant

1972

Trials

28 trials available for aminoglutethimide and Neoplasm Metastasis

ArticleYear
Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy.
    Anti-cancer drugs, 2004, Volume: 15, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic C

2004
Aminoglutethimide in the treatment of advanced breast cancer.
    Cancer treatment reviews, 1984, Volume: 11, Issue:3

    Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic;

1984
Ablative procedures in patients with metastatic breast carcinoma.
    Cancer, 1984, Feb-01, Volume: 53, Issue:3 Suppl

    Topics: Adrenal Cortex; Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Castration; Clinica

1984
Currently active protocols in the EORTC Breast Cancer Cooperative Group.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1984, Volume: 91

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials

1984
A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Cancer, 1982, Dec-01, Volume: 50, Issue:11

    Topics: Aminoglutethimide; Breast Neoplasms; Castration; Clinical Trials as Topic; Female; Humans; Menopause

1982
A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.
    The New England journal of medicine, 1981, Sep-03, Volume: 305, Issue:10

    Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Hormones; Huma

1981
Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast.
    Cancer research, 1982, Volume: 42, Issue:8 Suppl

    Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Hydroc

1982
Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.
    Cancer research, 1982, Volume: 42, Issue:8 Suppl

    Topics: Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Danazol; Drug Therapy, Combination; F

1982
[Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1981, Oct-02, Volume: 106, Issue:40

    Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause

1981
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
    La Clinica terapeutica, 1994, Volume: 145, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans

1994
Second-line hormonotherapy for breast cancer. Uselessness of first-line continuation.
    American journal of clinical oncology, 1993, Volume: 16, Issue:6

    Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; H

1993
A randomized trial on tamoxifen continuation during second-line hormone therapy in breast cancer.
    Annals of the New York Academy of Sciences, 1993, Nov-30, Volume: 698

    Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Middle Aged; Neoplasm Metastasi

1993
Second-line endocrine treatment of advanced breast cancer--a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35 Suppl 5

    Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Humans; Me

1996
Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
    Breast cancer research and treatment, 2000, Volume: 61, Issue:2

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined

2000
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Neoplasma, 2000, Volume: 47, Issue:2

    Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot

2000
A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer.
    Cancer, 1979, Volume: 43, Issue:6

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Cerebrospinal Fluid Rhinorrhea; Clinical Trials as

1979
Second line hormonal therapy with aminoglutethimide in metastatic breast cancer.
    Acta oncologica (Stockholm, Sweden), 1990, Volume: 29, Issue:6

    Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Estrogen An

1990
Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
    Breast cancer research and treatment, 1989, Volume: 14, Issue:2

    Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Megest

1989
Tamoxifen therapy of metastatic breast cancer.
    The Journal of laboratory and clinical medicine, 1987, Volume: 109, Issue:3

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clin

1987
[Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
    Onkologie, 1987, Volume: 10, Issue:5

    Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Combined Modal

1987
[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
    Bulletin du cancer, 1987, Volume: 74, Issue:3

    Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; D

1987
Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:6

    Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl

1986
Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
    Breast cancer research and treatment, 1986, Volume: 7 Suppl

    Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop

1986
Metastatic pattern and response to endocrine therapy in human breast cancer.
    Breast cancer research and treatment, 1986, Volume: 8, Issue:3

    Topics: Aminoglutethimide; Breast Neoplasms; Diethylstilbestrol; Female; Fluoxymesterone; Humans; Medroxypro

1986
Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer.
    Tumori, 1985, Jun-30, Volume: 71, Issue:3

    Topics: Age Factors; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle A

1985
Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:10

    Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; F

1985
Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.
    The Journal of clinical endocrinology and metabolism, 1967, Volume: 27, Issue:9

    Topics: Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Aminoglutethimide; Anim

1967
Effect of aminoglutethimide and reserpine on the human pituitary-adrenal axis: remission of a case of Cushing's disease.
    Metabolism: clinical and experimental, 1970, Volume: 19, Issue:10

    Topics: 17-Hydroxycorticosteroids; Addison Disease; Adrenal Glands; Adult; Aldosterone; Aminoglutethimide; A

1970

Other Studies

67 other studies available for aminoglutethimide and Neoplasm Metastasis

ArticleYear
Recognitive nano-thin-film composite beads for the enantiomeric resolution of the metastatic breast cancer drug aminoglutethimide.
    Journal of chromatography. A, 2014, Sep-05, Volume: 1358

    Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure

2014
Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen.
    Cancer, 1982, Nov-01, Volume: 50, Issue:9

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Dizziness; Edema; Female; Fever; Humans; Middle Ag

1982
[Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Onkologie, 1982, Volume: 5 Suppl

    Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations

1982
[Prognostic value of serum CEA and therapy-induced nonspecific CEA levels in metastasizing breast carcinoma].
    Onkologie, 1984, Volume: 7, Issue:6

    Topics: Adult; Aged; Alkaline Phosphatase; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined

1984
The use of aminoglutethimide in the treatment of patients with metastatic carcinoma of the breast.
    Cancer, 1980, Aug-15, Volume: 46, Issue:4 Suppl

    Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Aminoglutethimide; Antineoplastic Agents; Breast Neopla

1980
Response to aminoglutethimide after tamoxifen therapy in advanced breast cancer.
    The Medical journal of Australia, 1982, Jan-09, Volume: 1, Issue:1

    Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Drug Administration Sc

1982
Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer.
    The Medical journal of Australia, 1981, Feb-21, Volume: 1, Issue:4

    Topics: Adrenal Glands; Aminoglutethimide; Breast Neoplasms; Dehydroepiandrosterone; Dehydroepiandrosterone

1981
[Treatment of metastatic breast cancer with aminoglutethimide after failure of tamoxifen].
    Harefuah, 1984, Dec-16, Volume: 107, Issue:12

    Topics: Aminoglutethimide; Breast Neoplasms; Humans; Neoplasm Metastasis; Tamoxifen

1984
Aminoglutethimide as an aromatase inhibitor in the treatment of cancer.
    Cancer treatment reviews, 1984, Volume: 11, Issue:4

    Topics: Aminoglutethimide; Androgens; Animals; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Hu

1984
Aminoglutethimide for the treatment of advanced postmenopausal breast cancer.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:1

    Topics: Adult; Age Factors; Aged; Aminoglutethimide; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combin

1983
Choosing treatment for metastatic breast cancer.
    British medical journal (Clinical research ed.), 1982, Nov-20, Volume: 285, Issue:6353

    Topics: Aged; Aminoglutethimide; Breast Neoplasms; Female; Hormones; Humans; Middle Aged; Neoplasm Metastasi

1982
Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.
    Annals of internal medicine, 1982, Volume: 96, Issue:1

    Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Glucocorticoids; Humans; Menopaus

1982
Medical adrenalectomy in patients with advanced breast cancer.
    Cancer, 1982, Mar-15, Volume: 49, Issue:6

    Topics: Adrenal Glands; Adrenalectomy; Adult; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Female; Fl

1982
Is aminoglutethimide an alternative to adrenalectomy for metastatic carcinoma of the breast?
    Canadian journal of surgery. Journal canadien de chirurgie, 1982, Volume: 25, Issue:6

    Topics: Adrenalectomy; Adult; Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female;

1982
[Treatment of metastasizing breast cancer with aminoglutethimide].
    Acta medica Austriaca, 1982, Volume: 9, Issue:5-6

    Topics: Aged; Aminoglutethimide; Ataxia; Breast Neoplasms; Carcinoembryonic Antigen; Drug Resistance; Estrad

1982
Treatment of metastatic breast cancer with aminoglutethimide.
    Cancer, 1981, Apr-15, Volume: 47, Issue:8

    Topics: Aminoglutethimide; Breast Neoplasms; Dexamethasone; Female; Hormones; Humans; Middle Aged; Nausea; N

1981
Medical adrenalectomy with aminoglutethimide-cortisol in the treatment of metastatic breast carcinoma.
    European journal of cancer, 1980, Volume: Suppl 1

    Topics: Aged; Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Hydrocortisone

1980
Cancer of the breast: the past decade (second of two parts).
    The New England journal of medicine, 1980, Jan-10, Volume: 302, Issue:2

    Topics: Adrenalectomy; Adult; Age Factors; Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Castr

1980
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
    Journal of the National Cancer Institute, 1994, Feb-02, Volume: 86, Issue:3

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Flutamid

1994
Adrenal carcinoma.
    Current therapy in endocrinology and metabolism, 1994, Volume: 5

    Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aminoglutethimide; Carcinoma; Cushing Syndrome; Dia

1994
Aminoglutethimide in treatment of metastatic breast carcinoma.
    Lancet (London, England), 1978, Sep-23, Volume: 2, Issue:8091

    Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neopl

1978
Mechanism of action of aminoglutethimide in breast cancer.
    Lancet (London, England), 1979, Jan-06, Volume: 1, Issue:8106

    Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogen Antagonists;

1979
Pancytopenia induced by aminoglutethimide in the treatment of breast cancer.
    Cancer treatment reports, 1978, Volume: 62, Issue:10

    Topics: Aged; Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans;

1978
Breast carcinoma associated with Klinefelter syndrome: a case report.
    Journal of surgical oncology, 1978, Volume: 10, Issue:5

    Topics: Adrenal Glands; Adult; Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating;

1978
Metastatic medullary carcinoma of the thyroid complicated by Cushing's syndrome.
    The Medical journal of Australia, 1979, Mar-10, Volume: 1, Issue:5

    Topics: Adult; Aminoglutethimide; Carcinoma; Cushing Syndrome; Dexamethasone; Drug Therapy, Combination; Hum

1979
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
    Annals of surgery, 1978, Volume: 187, Issue:5

    Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Brea

1978
Experience with 6-aminoglutethimide in the treatment of metastatic breast cancer.
    Clinical oncology, 1978, Volume: 4, Issue:4

    Topics: Adrenal Glands; Aminoglutethimide; Betamethasone; Breast Neoplasms; Drug Therapy, Combination; Femal

1978
Aminoglutethimide for metastatic breast cancer.
    Annals of internal medicine, 1977, Volume: 86, Issue:6

    Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Neoplasm Metastasis

1977
Studies in patients with metastatic breast carcinoma treated with aminoglutethimide for medical adrenalectomy.
    Surgical forum, 1976, Volume: 27, Issue:62

    Topics: Adrenalectomy; Aminoglutethimide; Breast Neoplasms; Dexamethasone; Drug Therapy, Combination; Female

1976
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
    British journal of cancer, 1992, Volume: 65, Issue:1

    Topics: Adult; Aged; Aminoglutethimide; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Female; Follow-

1992
[Results of hormone therapy with aminoglutethimide (Rodazol) in postmenopausal metastatic breast cancer].
    Geburtshilfe und Frauenheilkunde, 1991, Volume: 51, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Huma

1991
[The use of aminoglutethimide in the treatment of metastatic breast cancer].
    Minerva ginecologica, 1991, Volume: 43, Issue:12

    Topics: Adrenal Glands; Age Factors; Aminoglutethimide; Androstenedione; Breast Neoplasms; Female; Humans; M

1991
[Reflexions on hormone therapy of cancer of the breast].
    Bulletin du cancer, 1991, Volume: 78, Issue:11 Suppl

    Topics: Aminoglutethimide; Androgens; Breast Neoplasms; Estrogens; Female; Humans; Medroxyprogesterone Aceta

1991
[Hormonal control of disseminated breast cancer].
    Sovetskaia meditsina, 1990, Issue:6

    Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Delayed-Action Preparations; Estrogen An

1990
Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:7

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast N

1990
[Experiences with Rodazol therapy in the treatment of postmenopausal patients with metastatic breast cancer].
    Zentralblatt fur Gynakologie, 1990, Volume: 112, Issue:17

    Topics: Administration, Oral; Aminoglutethimide; Breast Neoplasms; Drug Administration Schedule; Female; Fol

1990
[Palliative treatment of skeletal metastases in patients with breast carcinoma].
    Nederlands tijdschrift voor geneeskunde, 1987, Jun-20, Volume: 131, Issue:25

    Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Megestrol; Neoplasm Metastasis; Palliative Care

1987
A study of aminoglutethemide and hydrocortisone in patients with advanced and refractory prostate carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:4

    Topics: Aminoglutethimide; Carcinoma; Drug Evaluation; Drug Therapy, Combination; Humans; Hydrocortisone; Ma

1989
[Value of hormone therapy in metastasizing breast cancer].
    Wiener medizinische Wochenschrift (1946), 1985, Dec-31, Volume: 135, Issue:23-24

    Topics: Aminoglutethimide; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Medroxyprogesterone; Med

1985
Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
    Cancer, 1986, Nov-01, Volume: 58, Issue:9

    Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea

1986
Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1985, Volume: 11, Issue:1

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis;

1985
Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Aminoglutethimide; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Hydrocortisone; Medr

1985
[Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
    Onkologie, 1985, Volume: 8, Issue:2

    Topics: Aminoglutethimide; Breast Neoplasms; Cholesterol; Cortisone; Drug Therapy, Combination; Female; Huma

1985
A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
    American journal of clinical oncology, 1988, Volume: 11, Issue:5

    Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr

1988
Combination hormone therapy for metastatic breast cancer. An ECOG study of megestrol and aminoglutethimide.
    Cancer, 1987, Nov-01, Volume: 60, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; B

1987
[The use of aminoglutethimide (orimeten) in disseminated breast cancer].
    Voprosy onkologii, 1987, Volume: 33, Issue:5

    Topics: Adult; Aminoglutethimide; Breast Neoplasms; Female; Follow-Up Studies; Humans; Menopause; Middle Age

1987
Aminoglutethimide as second-line hormonal therapy in advanced breast cancer: response and toxicity.
    Human toxicology, 1987, Volume: 6, Issue:3

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Female; Humans; Hydrocortisone; Middle Aged; Neopl

1987
[Aminoglutethimide in the treatment of metastasizing breast carcinoma in old age].
    Chirurgia italiana, 1987, Volume: 39, Issue:2

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Female; Humans; Menopause; Middle Aged

1987
Aminoglutethimide in metastatic adenocarcinoma of the prostate.
    Progress in clinical and biological research, 1987, Volume: 243A

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Aminoglutethimide; Humans; Hydrocortisone; Male; Mid

1987
Endocrine therapy of metastatic breast cancer.
    The Keio journal of medicine, 1987, Volume: 36, Issue:3

    Topics: Aminoglutethimide; Breast Neoplasms; Female; Humans; Neoplasm Metastasis; Ovariectomy; Progesterone

1987
Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.
    Cancer chemotherapy and pharmacology, 1987, Volume: 20, Issue:4

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Foll

1987
[Low-dose aminoglutethimide therapy without cortisol substitution in postmenopause metastasizing breast cancer].
    Medizinische Klinik (Munich, Germany : 1983), 1986, Oct-03, Volume: 81, Issue:20

    Topics: Aminoglutethimide; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Huma

1986
Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:11

    Topics: Adult; Aminoglutethimide; Breast Neoplasms; Cortisone; Female; Humans; Menopause; Middle Aged; Neopl

1986
Chemotherapy and hormone therapy of metastatic breast cancer.
    The Southeast Asian journal of tropical medicine and public health, 1985, Volume: 16, Issue:4

    Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modali

1985
Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:4

    Topics: Aged; Aminoglutethimide; Castration; Combined Modality Therapy; Estrogens; Follow-Up Studies; Humans

1985
Aminoglutethimide-induced hematologic toxicity: worldwide experience.
    Cancer treatment reports, 1985, Volume: 69, Issue:9

    Topics: Aminoglutethimide; Blood Cell Count; Breast Neoplasms; Female; Global Health; Hematologic Diseases;

1985
Rationale for suppression of adrenal steroidogenesis in advanced prostatic cancer.
    Progress in clinical and biological research, 1985, Volume: 185A

    Topics: Adrenal Cortex Hormones; Aminoglutethimide; Androgen Antagonists; Androgens; Animals; Estrogens; Hum

1985
[Aminoglutethimide therapy in advanced breast cancer].
    Wiener medizinische Wochenschrift (1946), 1985, Dec-31, Volume: 135, Issue:23-24

    Topics: Adult; Aged; Aminoglutethimide; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Middle

1985
Malignant melanoma with ectopic production of adrenocorticotropic hormone. Palliative treatment with inhibitors of adrenal steroid biosynthesis.
    The Journal of clinical endocrinology and metabolism, 1973, Volume: 36, Issue:3

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenocortical Hyperfunction; Adrenocorticotropic Hormon

1973
Oat cell carcinoma of the pancreas with ectopic ACTH secretion.
    Cancer, 1973, Volume: 31, Issue:6

    Topics: Adrenocorticotropic Hormone; Aminoglutethimide; Autopsy; Biopsy; Carcinoma, Bronchogenic; Carcinoma,

1973
ACTH, glucagon and gastrin production by a pancreatic islet cell carcinoma and its treatment.
    Clinical endocrinology, 1973, Volume: 2, Issue:4

    Topics: Adenoma, Islet Cell; Adrenocorticotropic Hormone; Adult; Aminoglutethimide; Gastrins; Glucagon; Horm

1973
Adrenal suppression in the treatment of carcinoma of the prostate.
    British journal of urology, 1974, Volume: 46, Issue:5

    Topics: Acid Phosphatase; Administration, Oral; Adrenal Glands; Aged; Alkaline Phosphatase; Aminoglutethimid

1974
Preliminary trial of aminoglutethimide in breast cancer.
    Cancer, 1973, Volume: 32, Issue:1

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Administration, Oral; Aminoglutethimide; Antineoplastic

1973
Proceedings: Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer.
    Cancer, 1974, Volume: 33, Issue:2

    Topics: Adrenal Glands; Adrenalectomy; Adult; Aged; Aminoglutethimide; Binding, Competitive; Breast Neoplasm

1974
Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma.
    British medical journal, 1971, Nov-13, Volume: 4, Issue:5784

    Topics: Age Factors; Aged; Aminoglutethimide; Castration; Diethylstilbestrol; Estrogens; Humans; Male; Middl

1971
Amino-glutethimide (elipten) in adenocortical carcinoma.
    Boletin de la Asociacion Medica de Puerto Rico, 1968, Volume: 60, Issue:12

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Gland Neoplasms; Adrenocortical Hyperfunction; A

1968
Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome.
    JAMA, 1966, Nov-28, Volume: 198, Issue:9

    Topics: Adrenal Gland Neoplasms; Adult; Aminoglutethimide; Anticonvulsants; Antineoplastic Agents; Carbon Is

1966